iconEarnings Announcement After Market Close

Regenxbio Inc RGNX:NASDAQ

RT Quote | NASDAQ | USD
Last | 02/26/21 EST
40.91quote price arrow up+0.93 (+2.33%)
Volume
389,570
52 week range
20.03 - 50.26

...

Loading . . .

KEY STATS

  • Open40.10
  • Day High41.33
  • Day Low38.97
  • Prev Close40.91
  • 52 Week High50.26
  • 52 Week High Date01/14/21
  • 52 Week Low20.03
  • 52 Week Low Date03/18/20
  • Market Cap1.704B
  • Shares Out41.66M
  • 10 Day Average Volume0.39M
  • Dividend-
  • Dividend Yield-
  • Beta1.19
  • 1 Year % Change-13.87

RATIOS/PROFITABILITY

  • EPS (TTM)-2.48
  • P/E (TTM)-16.52
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-97.681M
  • ROE (MRQ)-20.69%
  • Revenue (MRQ)144.89M
  • Gross Margin (MRQ)79.81%
  • Net Margin (MRQ)-63.13%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date03/01/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

QUOTE FINDER

Profile

MORE
REGENXBIO Inc. is a clinical-stage biotechnology company. The Company's gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases. Its product candidate, RGX-314, is meant for the treatment of wet...
Allan Fox J.D.
Chairman
Kenneth Mills
President
Vittal Vasista
Chief Financial Officer
Address
9600 Blackwell Rd Ste 210
Rockville, MD
20850-3655
United States